Wegovy vs Ozempic: Same Drug, Different Doses, Different FDA Approvals

Two Brand Names, One Molecule — But the Differences Are Clinically Significant

Wegovy and Ozempic are both brand names for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. The active compound is chemically identical. Yet they represent distinct regulatory approvals, distinct dosing regimens, and distinct insurance coverage profiles — differences that determine who can access them, what insurers will pay for, and how much weight loss or glycemic improvement a patient can expect. Conflating them is not merely a branding error; it has practical consequences for prescribers and patients alike.

Side-by-Side Comparison

Why the Dose Difference Matters

The dose difference between Ozempic and Wegovy is not incidental — it's the reason Wegovy produces significantly greater weight loss. In the SUSTAIN trials for Ozempic at 1 mg, patients lost approximately 6–7% of body weight. In the STEP 1 trial using Wegovy's 2.4 mg dose, average loss reached 14.9%. The dose-response relationship for semaglutide is steep: doubling the dose from 1 mg to 2 mg in Ozempic's own prescribing expansion (approved in 2022) showed additional glycemic and modest additional weight benefits.

The titration schedules also differ. Wegovy follows a 16-week escalation — 0.25 mg for 4 weeks, 0.5 mg, 1 mg, 1.7 mg, then 2.4 mg maintenance — specifically designed to minimize gastrointestinal side effects at the higher target dose. Ozempic escalates more quickly to its lower maintenance doses.

Who Qualifies for Each

Ozempic Qualifications

• Diagnosed type 2 diabetes mellitus requiring additional glycemic control
• Adults with T2D and established cardiovascular disease seeking MACE risk reduction
• Adults with T2D and chronic kidney disease (eGFR 25–75 mL/min/1.73 m²) seeking kidney protection
• Off-label prescribing for weight loss occurs but lacks FDA backing and insurance coverage

Wegovy Qualifications

• Adults with BMI ≥ 30 kg/m² (obesity), or
• Adults with BMI ≥ 27 kg/m² plus at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, sleep apnea)
• Intended for use alongside reduced-calorie diet and increased physical activity

The Insurance Labyrinth

Despite being the same molecule, Ozempic and Wegovy face entirely different insurance landscapes in the United States. Ozempic is covered by most commercial insurers and Medicare for its diabetes indication — it appears on formularies and typically costs $25–60/month with coverage. Wegovy has historically faced more barriers: many commercial plans require prior authorization, step therapy (trying cheaper alternatives first), or deny coverage for obesity treatment altogether, as obesity was historically excluded from insurance coverage as a "lifestyle issue."

The Inflation Reduction Act of 2022 and subsequent CMS guidance have expanded Medicare coverage for anti-obesity medications, but implementation varies. Medicaid coverage for Wegovy remains patchy across states. The result is a significant access disparity: the same drug at the same dose is covered or denied based entirely on which box gets checked on the prescription form.

The SELECT Trial Changed Wegovy's Profile

In 2024, the FDA expanded Wegovy's label to include cardiovascular risk reduction — specifically reducing the risk of cardiovascular death, heart attack, and stroke in adults with obesity and established cardiovascular disease. This added indication came from the SELECT trial, which enrolled over 17,500 adults and found a 20% reduction in major adverse cardiovascular events versus placebo over a median 3.3 years. Critically, SELECT participants did not need type 2 diabetes — two-thirds were non-diabetic. This was the first time an anti-obesity drug demonstrated a cardiovascular outcome benefit, blurring the line between Ozempic's traditional CV-indication territory and Wegovy's expanded scope.

Switching Between the Two

Physicians sometimes switch patients from Ozempic to Wegovy when the primary goal becomes weight management rather than glycemic control, particularly if a patient with well-controlled diabetes wants maximum weight loss. The switch requires confirming the higher dose is tolerated and ensuring insurance will cover the change. Some prescribers have also prescribed Ozempic at its 2 mg dose for patients who need weight loss but can only get insurance coverage under the diabetes indication — a situation that illustrates how regulatory and insurance frameworks have not kept pace with the science of these drugs.

This article is for informational purposes only. Consult a qualified healthcare professional before making medical decisions.